MedTrace Logo

Cardiac Stem Cell Infusion in Patients With Ischemic CardiOmyopathy (SCIPIO)

NCT00474461 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2017-04-11

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety of intracoronary cardiac stem cells (CSCs) therapy in humans. Currently, there is no effective intervention to regenerate (regrow) dead heart muscle after a heart attack.

The central hypothesis is that CSCs infused into nonviable myocardial segments will regenerate infarcted myocardium by differentiating into cardiomyocytes and other cell types. According to our hypothesis, CSC infusion regenerates myocardium with consequent improvement in contractile function of the heart and general clinical status.

Conditions

Interventions

BIOLOGICAL

Treatment group

Intracoronary injection of cardiac stem cells

Sponsors & Collaborators

  • Brigham and Women's Hospital

    collaborator OTHER

  • Jewish Hospital and St. Mary's Healthcare

    collaborator OTHER

  • University of Louisville

    lead OTHER

Principal Investigators

  • Roberto Bolli, MD · University of Louisville

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2013-08-31
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00474461 on ClinicalTrials.gov